Zobrazeno 1 - 10
of 94
pro vyhledávání: '"Alina Berriolo"'
Autor:
Bruno Coudert, Jean-Yves Pierga, Marie-Ange Mouret-Reynier, Kaldoun Kerrou, Jean-Marc Ferrero, Thierry Petit, Fanny Le Du, Pierre-François Dupré, Thomas Bachelot, Philippe Gabelle, Marie-Pierre Chauvet, David Coeffic, Catherine Barbe, Jean-Briac Prevost, Gilles Paintaud, Gilles Thibault, Abdennour Ferhat, Julien Dupin, Alina Berriolo-Riedinger, Laurent Arnould
Publikováno v:
EClinicalMedicine, Vol 28, Iss , Pp 100566- (2020)
Background: The open-label, randomised Phase 2 AVATAXHER study (NCT01142778) demonstrated that early PET assessment identified HER2-positive breast cancer patients who responded poorly to neoadjuvant docetaxel plus trastuzumab. Adding neoadjuvant bev
Externí odkaz:
https://doaj.org/article/e12828e210e34b18a595bb3ec526544b
Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project
Autor:
Clément Bailly, Thomas Carlier, Alina Berriolo-Riedinger, Olivier Casasnovas, Emmanuel Gyan, Michel Meignan, Anne Moreau, Barbara Burroni, Loïc Djaileb, Remy Gressin, Anne Devillers, Thierry Lamy, Catherine Thieblemont, Olivier Hermine, Françoise Kraeber-Bodéré, Steven Le Gouill, Caroline Bodet-Milin
Publikováno v:
Haematologica, Vol 105, Iss 1 (2020)
Externí odkaz:
https://doaj.org/article/8ee7f597f7b64382a011c7c0ce3bc361
Autor:
Marie-Hélène Delfau-Larue, Axel van der Gucht, Jehan Dupuis, Jean-Philippe Jais, Isabelle Nel, Asma Beldi-Ferchiou, Salma Hamdane, Ichrafe Benmaad, Gaelle Laboure, Benjamin Verret, Corinne Haioun, Christiane Copie-Bergman, Alina Berriolo-Riedinger, Philippine Robert, René-Olivier Casasnovas, Emmanuel Itti
Publikováno v:
Blood Advances, Vol 2, Iss 7, Pp 807-816 (2018)
Abstract: Outcomes for follicular lymphoma (FL) have greatly improved, but most patients will ultimately relapse. High total metabolic tumor volume (TMTV), computed from baseline 18F-fluorodeoxyglucose–positron emission tomography (PET), is associa
Externí odkaz:
https://doaj.org/article/52d5dd863f63494f8e1f47287b4fc546
Autor:
Edouard Depardon, Salim Kanoun, Olivier Humbert, Aurélie Bertaut, Jean-Marc Riedinger, Ilan Tal, Jean-Marc Vrigneaud, Maud Lasserre, Michel Toubeau, Alina Berriolo-Riedinger, Inna Dygai-Cochet, Pierre Fumoleau, François Brunotte, Alexandre Cochet
Publikováno v:
PLoS ONE, Vol 13, Iss 7, p e0199529 (2018)
AIM:Evaluate response and predict prognosis of patients with newly diagnosed metastatic breast cancer treated with first line systemic therapy using European Organization for Research and Treatment of Cancer (EORTC) criteria and PET Response Criteria
Externí odkaz:
https://doaj.org/article/ebc3478036f5453c96d9f39fb219bdb1
Autor:
Salim Kanoun, Ilan Tal, Alina Berriolo-Riedinger, Cédric Rossi, Jean-Marc Riedinger, Jean-Marc Vrigneaud, Louis Legrand, Olivier Humbert, Olivier Casasnovas, François Brunotte, Alexandre Cochet
Publikováno v:
PLoS ONE, Vol 10, Iss 10, p e0140830 (2015)
To investigate the respective influence of software tool and total metabolic tumor volume (TMTV0) calculation method on prognostic stratification of baseline 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography ([18F]FDG-PET) in newly diagnos
Externí odkaz:
https://doaj.org/article/b2f38c70aee14c5cbd0790504604cc89
Autor:
Aspasia Stamatoullas, Hervé Ghesquières, Pierre Feugier, Marc André, Fabien Le Bras, Anne-Claire Gac, Cécile Borel, Thomas Gastinne, Philippe Quittet, Franck Morschhauser, Vincent Ribrag, Stephanie Guidez, Emmanuelle Nicolas-Virelizier, Alina Berriolo-Riedinger, Thierry Vander Borght, Véronique Edeline, Pauline Brice
Publikováno v:
Leukemia & lymphoma, Vol. 63, no. 13, p. 3063-3071 (2022)
Leukemia & lymphoma
Leukemia & lymphoma, 2022, Leukemia & lymphoma, 63 (13), pp.3063-3071. ⟨10.1080/10428194.2022.2107204⟩
Leukemia & lymphoma
Leukemia & lymphoma, 2022, Leukemia & lymphoma, 63 (13), pp.3063-3071. ⟨10.1080/10428194.2022.2107204⟩
This phase I/II study assessed the combination of brentuximab vedotin (BV) with ifosfamide-carboplatin-etoposide (ICE) as a second-line therapy in refractory/relapsed (R/R) classical Hodgkin lymphoma (cHL) patients. Phase I study was designed to dete
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20fdb64fb1e07e41eefce23ded0ee6d9
https://doi.org/10.1080/10428194.2022.2107204
https://doi.org/10.1080/10428194.2022.2107204
Autor:
René-Olivier Casasnovas, Reda Bouabdallah, Pauline Brice, Julien Lazarovici, Hervé Ghesquieres, Aspasia Stamatoullas, Jehan Dupuis, Anne-Claire Gac, Thomas Gastinne, Bertrand Joly, Krimo Bouabdallah, Emmanuelle Nicolas-Virelizier, Pierre Feugier, Franck Morschhauser, David Sibon, Christophe Bonnet, Alina Berriolo-Riedinger, Véronique Edeline, Marie Parrens, Diane Damotte, Diane Coso, Marc André, Michel Meignan, Cédric Rossi
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, no. 10, p. 1091-1101 (2022)
PURPOSE The AHL2011 study (ClinicalTrials.gov identifier: NCT01358747 ) demonstrated that a positron emission tomography (PET)-driven de-escalation strategy after two cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aeb3972798df180330d244afe67ffbce
https://doi.org/10.1200/jco.21.01777
https://doi.org/10.1200/jco.21.01777
Autor:
François Brunotte, Alexandre Cochet, Pierre Fumoleau, Charles Coutant, Salim Kanoun, Véronique Lorgis, Isabelle Desmoulins, Alina Berriolo-Riedinger, Céline Charon-Barra, Jean-Marc Riedinger, Olivier Humbert
Purpose: To investigate the value of the metabolic tumor response assessed with 18F-fluorodeoxyglucose positron emission tomography (FDG-PET), compared with clinicobiologic markers to predict pathologic complete response (pCR) to neoadjuvant chemothe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9d6c76a801cda339116147592f4c23c
https://doi.org/10.1158/1078-0432.c.6524931.v1
https://doi.org/10.1158/1078-0432.c.6524931.v1
Autor:
François Brunotte, Alexandre Cochet, Pierre Fumoleau, Charles Coutant, Salim Kanoun, Véronique Lorgis, Isabelle Desmoulins, Alina Berriolo-Riedinger, Céline Charon-Barra, Jean-Marc Riedinger, Olivier Humbert
Supplementary Figure 1: Graphical display of changes in primary tumor SUVmax between baseline and interim 18F-FDG PET exams.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68782a283e4e2d2685c4fcf2ef41f9f7
https://doi.org/10.1158/1078-0432.22461861.v1
https://doi.org/10.1158/1078-0432.22461861.v1
Autor:
Catherine Thieblemont, Loic Chartier, Ulrich Dührsen, Umberto Vitolo, Sally F. Barrington, Jan M. Zaucha, Laetitia Vercellino, Maria Gomes Silva, Ines Patrocinio-Carvalho, Pierre Decazes, Pierre-Julien Viailly, Herve Tilly, Alina Berriolo-Riedinger, Oliver Casasnovas, Andreas Hüttmann, Hajira Ilyas, N. George Mikhaeel, Joel Dunn, Anne-Ségolène Cottereau, Christine Schmitz, Lale Kostakoglu, Joseph N. Paulson, Tina Nielsen, Michael Meignan
Publikováno v:
Blood Advances
Blood Advances, 2022, 6 (23), pp.5995-6004. ⟨10.1182/bloodadvances.2021006923⟩
Blood Advances, 2022, 6 (23), pp.5995-6004. ⟨10.1182/bloodadvances.2021006923⟩
Aggressive large B-cell lymphoma (LBCL) has variable outcomes. Current prognostic tools use factors for risk stratification that inadequately identify patients at high risk of refractory disease or relapse before initial treatment. A model associatin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::311cc51460cc36c205196479b3e6b1db
https://www.hal.inserm.fr/inserm-03924551/file/main.pdf
https://www.hal.inserm.fr/inserm-03924551/file/main.pdf